Petmed Express Inc (PETS) FinancialsPETSPetmed Express Inc

PetMed Express, Inc. (PETS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Reorder sales, accounting for 80.1% of total sales, equivalent to $32.84M. Other significant revenue streams include New order sales and Membership fees. Understanding this composition is critical for investors evaluating how PETS navigates market cycles within the Drug Retailers industry.

Evaluating the bottom line, PetMed Express, Inc. maintains a gross margin of 22.39%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -15.19%, while the net margin is -14.98%. These profitability ratios, combined with a Return on Equity (ROE) of -78.58%, provide a clear picture of how effectively PETS converts its operational activities into shareholder value.

In the context of the broader market, PETS competes directly with industry leaders such as TLF and SPWH. With a market capitalization of $26.45M, it holds a significant position in the sector. When comparing efficiency, PETS's gross margin of 22.39% stands against TLF's 64.81% and SPWH's 32.48%. Such benchmarking helps identify whether PetMed Express, Inc. is trading at a premium or discount relative to its financial performance.

Petmed Express has shown declining financial performance, with Q3 2026 revenue at $40.66 million, down from $51.96 million in Q3 2025. The company has reported negative net income for multiple quarters, with a net income of -$10.55 million in Q3 2026 and a gross margin of only 22.58%.